Filtros de búsqueda

Lista de obras de Roberto Iacovelli

Abiraterone acetate in castration-resistant prostate cancer

artículo científico

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

artículo científico publicado en 2017

Adjuvant therapy in renal cell carcinoma.

artículo científico publicado en 2017

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

artículo científico publicado en 2015

Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer

artículo científico publicado en 2018

Biomarkers of response to advanced prostate cancer therapy

scientific article published on 27 January 2020

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma

artículo científico publicado en 2015

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on im

artículo científico publicado en 2021

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

artículo científico publicado en 2019

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

artículo científico publicado en 2020

Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients

scientific article published on 31 March 2019

Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma

scientific article published on 01 February 2019

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

article

Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.

artículo científico publicado en 2017

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

artículo científico publicado en 2014

Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

artículo científico publicado en 2017

Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma

scientific article published on 01 December 2011

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

artículo científico publicado en 2015

Circulating tumor cells in genitourinary tumors.

artículo científico publicado en 2017

Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney.

artículo científico publicado en 2013

Clinical and pathological features of primary renal angiosarcoma

artículo científico

Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature.

artículo científico publicado en 2012

Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma

artículo científico publicado en 2015

Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum

artículo científico publicado en 2007

Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature

artículo científico publicado en 2015

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

artículo científico publicado en 2017

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort

artículo científico publicado en 2013

Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib

artículo científico publicado en 2014

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

artículo científico publicado en 2015

Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer

artículo científico publicado en 2018

Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma

artículo científico publicado en 2015

Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

artículo científico publicado en 2020

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

artículo científico publicado en 2020

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

artículo científico publicado en 2015

De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?

scientific article published on 20 July 2018

Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma

artículo científico publicado el 1 de diciembre de 2010

Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

artículo científico publicado en 2015

Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.

artículo científico publicado en 2013

ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance

artículo científico publicado en 2018

Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer

scientific article published on 28 December 2018

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma

artículo científico publicado en 2013

Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis.

artículo científico publicado en 2021

Emerging tyrosine kinase inhibitors for the treatment of renal cancer

artículo científico

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data

artículo científico publicado en 2014

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

artículo científico publicado en 2014

Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature

artículo científico publicado en 2018

FOLFIRI with cetuximab or bevacizumab: FIRE-3

scientific article published on 24 November 2014

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

artículo científico publicado en 2014

Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma

artículo científico publicado en 2020

First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile

artículo científico publicado en 2013

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

artículo científico publicado en 2015

Follow-up of high-grade squamous intra-epithelial lesions (H-SIls) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. analysis of risk factors

artículo científico publicado en 2006

Future perspectives for personalized immunotherapy in renal cell carcinoma.

artículo científico

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

artículo científico publicado en 2014

Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib

artículo científico publicado en 2012

Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions

artículo científico publicado en 2019

Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside

artículo científico publicado en 2014

Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer

artículo científico publicado en 2014

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

artículo científico publicado en 2016

Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis

artículo científico publicado en 2018

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

artículo científico publicado en 2014

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.

artículo científico publicado en 2014

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

artículo científico publicado en 2012

Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis

artículo científico publicado en 2015

Inside the 2015 ASCO Genitourinary Cancers Symposium.

artículo científico publicado en 2015

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer

artículo científico publicado en 2016

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.

artículo científico publicado en 2016

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

scientific article published on 07 May 2018

Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?

artículo científico publicado en 2010

Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases

artículo científico publicado en 2012

Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.

artículo científico publicado en 2016

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience

scientific article published on 01 August 2018

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

artículo científico publicado en 2020

Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment

artículo científico

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

artículo científico publicado en 2012

Metabolic phenotype of bladder cancer

artículo científico publicado en 2016

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

scientific article published on 19 July 2019

Methylation study of the Paris system for reporting urinary (TPS) categories

artículo científico publicado en 2020

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients

artículo científico publicado en 2010

Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.

artículo científico publicado en 2012

Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies

artículo científico publicado en 2018

Neoadjuvant targeted therapy in renal cell carcinoma

artículo científico publicado en 2010

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study

article

PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer

scientific article published on 01 September 2019

PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis

artículo científico publicado en 2019

Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors

artículo científico publicado en 2020

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

artículo científico publicado en 2016

Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy

artículo científico publicado en 2018

Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer

artículo científico publicado en 2019

Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert

artículo científico publicado en 2012

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

artículo científico publicado en 2015

Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma

scientific article published on 06 October 2018

Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. A multicenter study

artículo científico publicado en 2006

Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis

artículo científico publicado en 2015

Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.

artículo científico publicado en 2014

Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.

artículo científico publicado en 2016

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study

article

Prostate cancer heterogeneity: Discovering novel molecular targets for therapy

artículo científico publicado en 2017

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

artículo científico publicado en 2020

Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma

artículo científico publicado en 2014

Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Ur

artículo científico publicado en 2016

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

scientific article published on 30 December 2019

Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents.

artículo científico publicado en 2018

Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research

Renal cell carcinoma: incidence and cost estimation in the era of targeted therapy

artículo científico publicado en 2010

Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher".

artículo científico publicado en 2013

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story

scientific article published on 10 October 2019

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials

artículo científico publicado en 2014

Role of MGMT as biomarker in colorectal cancer

artículo científico publicado en 2014

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program

artículo científico publicado en 2019

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

article

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study

artículo científico publicado en 2018

Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative gr

article

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

artículo científico publicado en 2019

Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis

artículo científico publicado en 2019

Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.

artículo científico publicado en 2016

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

artículo científico publicado en 2015

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies

artículo científico publicado en 2013

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

artículo científico publicado en 2014

Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?

artículo científico publicado en 2014

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma

artículo científico publicado en 2014

Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors

artículo científico publicado en 2014

Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

artículo científico

Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor

artículo científico publicado en 2014

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

artículo científico publicado en 2011

Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies

artículo científico publicado en 2019

Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

artículo científico publicado en 2014

The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis

scientific article published on 01 April 2020

The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.

artículo científico publicado en 2017

The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome

artículo científico publicado en 2017

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

artículo científico publicado en 2015

The development of PARP as a successful target for cancer therapy

artículo científico publicado en 2017

The effect of a treatment delay on outcome in metastatic renal cell carcinoma

artículo científico publicado en 2019

The end of chemotherapy in renal cell carcinoma: for much but not for all

scientific article published on 01 October 2010

The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer.

artículo científico publicado en 2015

The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies

artículo científico publicado en 2017

The origin of prostate metastases: emerging insights.

artículo científico

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

artículo científico publicado en 2018

The prognostic value of pain in castration-sensitive prostate cancer

artículo científico publicado en 2020

The prospect of precision therapy for renal cell carcinoma

artículo científico publicado en 2016

Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients

Toward a genome-based treatment landscape for renal cell carcinoma

scientific article published on 02 August 2019

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

artículo científico publicado en 2019

Treatment of collecting duct carcinoma: current status and future perspectives

artículo científico publicado en 2014

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.

artículo científico

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data

artículo científico publicado en 2013

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma

scientific article published on 26 October 2012

Umbilical node as first clinical appearance in a patient with a high tumor burden

scientific article published on 01 November 2011

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey

artículo científico publicado en 2012

Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up

artículo científico publicado en 2007

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda